Introduction {#Sec1}
============

Breast cancer is the most commonly diagnosed tumor type in women in the United States with a significant proportion developing metastatic disease \[[@CR1]\]. Metastatic breast cancer (MBC) is an incurable disease, and systemic treatment aims to prolong survival, control disease progression, alleviate symptoms, and enhance patient quality of life. Although early detection and improvements in therapy have augmented survival rates in recent years (5-year relative survival is 99 % for localized disease and 84 % for regional disease), the 5-year survival rates for patients with distant-stage disease remains low at 23 % \[[@CR1]\].

Control of several cellular processes in breast cancer is dependent on the epidermal growth factor receptor (EGFR, also known as ErbB) family, and members of this family have been proposed as targets in cancer therapy. Amplification of human epidermal growth factor receptor 2 (HER2/ErbB2) leads to increased receptor homo- and hetero-dimerization and subsequent activation of downstream signaling pathways associated with cell proliferation, differentiation, survival, and angiogenesis \[[@CR2]\]. Initial studies indicated that 20--25 % of tumors in women with early stage I--III breast cancers were HER2 positive \[[@CR3], [@CR4]\]. However, a larger and more recent study from Europe has reported HER2-positive breast cancer rates in the range of 13--19 % \[[@CR5]\] which has both prognostic and predictive implications \[[@CR3], [@CR6]\].

HER2-positive tumors are associated with particularly aggressive disease and a poor prognosis with shorter overall survival (OS) and disease-free survival intervals \[[@CR3]\]. Studies have shown that HER2-positive tumors are more likely to disseminate to major visceral sites as well as the central nervous system (CNS) \[[@CR7], [@CR8]\].

Trastuzumab, a monoclonal antibody directed against the HER2 receptor, has clinical activity in patients with HER2-positive breast carcinoma and is widely used in combination with cytotoxic agents \[[@CR9]--[@CR11]\]. A significant number of patients with HER2-positive MBC who are treated with trastuzumab experience symptomatic CNS metastases, potentially due to ineffective penetration of the CNS. Trastuzumab resistance may also develop, limiting trastuzumab's ability to maintain disease control in the advanced as well as early stage disease settings \[[@CR12]\]. As such, alternative therapeutic strategies and combinations need to be developed to target HER2 signaling.

Lapatinib (Tykerb/Tyverb^®^, GlaxoSmithKline) is an orally active small molecule that inhibits the tyrosine kinase activity of HER2 and EGFR. Lapatinib has shown clinical activity in combination with capecitabine in HER2-positive tumors that progressed while on standard treatment, including trastuzumab \[[@CR13]\]. Lapatinib, in combination with capecitabine was approved in 2007 by the U.S. Food and Drug Administration (US FDA) for the treatment of patients with advanced or MBC with HER2-positive tumors who have received prior therapy including an anthracycline, a taxane, and trastuzumab \[[@CR14]\]. Lapatinib in combination with letrozole (an aromatase inhibitor) has also been shown to be effective in the treatment of post-menopausal women with hormone receptor-positive, HER2-positive MBC \[[@CR15]\]. In 2010, the US FDA granted accelerated approval to lapatinib for use in combination with letrozole for the treatment of patients with HER2-positive MBC and for whom hormonal therapy is indicated \[[@CR14]\].

Nanoparticle albumin-bound paclitaxel (*nab*-paclitaxel; Abraxane^®^ for Injectable Suspension, Celgene Corporation) is a novel Cremophor^®^ EL-free, non-crystalline, amorphous, albumin-bound nanoparticle formulation of paclitaxel suspended in normal saline. It is associated with a lower risk of hypersensitivity as well as an improved toxicity profile, and has no requirements for premedication compared with solvent-based paclitaxel \[[@CR16]\]. Furthermore, the neuropathy that frequently accompanies paclitaxel administration was easily managed and resolved more rapidly in patients treated with *nab*-paclitaxel \[[@CR16]\]. *Nab*-paclitaxel demonstrated significantly longer progression-free survival (PFS), compared with docetaxel, in patients with MBC \[[@CR17], [@CR18]\]. *Nab*-paclitaxel has been approved by the US FDA in 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated \[[@CR19]\].

In early as well as advanced HER2-positive breast cancer, synergy between chemotherapy and HER2-directed therapy (such as trastuzumab) has significantly improved outcomes, including survival, compared with chemotherapy alone \[[@CR10], [@CR11]\]. However, despite treatment with taxane-based trastuzumab regimens in early stage disease, disease progressions are still evident. The proven activity of lapatinib in this setting (due to its differing mechanism of action) demonstrates that it is a suitable option in HER2-positive MBC. Unlike trastuzumab, it has been suggested that lapatinib can cross the blood--brain barrier, providing a rationale for testing lapatinib in patients with CNS metastases \[[@CR20], [@CR21]\]. Studies have also shown that HER3 can be transphosphorylated by p95 HER2 (a truncated version lacking the extracellular domain) in HER2-overexpressing breast cancer cell lines, and that this phosphorylation is inhibited by lapatinib, but not trastuzumab \[[@CR22]\]. A more recent study demonstrated an OS benefit with lapatinib in combination with trastuzumab for patients with HER2-positive MBC \[[@CR23]\]. Also, owing to the toxicity of solvent-based paclitaxel, evaluation of lapatinib in conjunction with *nab*-paclitaxel for the treatment of HER2-positive MBC is warranted.

Presented here are the results of a single-arm, multicenter Phase II study undertaken to determine the activity of lapatinib plus *nab*-paclitaxel in the first- and second-line setting in HER2-positive MBC.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This was an open-label, single-arm, multicenter, Phase II study (NCT00709761) to evaluate the efficacy and safety of *nab*-paclitaxel plus lapatinib in women with HER2-positive MBC who had received no more than one prior chemotherapeutic regimen in the metastatic setting. The planned enrollment was 60 patients with a lead in evaluation of the first 10 patients for safety of this combination. A safety analysis of the first ten enrolled patients treated for at least one cycle of the initial doses of *nab*-paclitaxel (125 mg/m^2^ IV on Day 1, 8, and 15 every 28 days) in combination with lapatinib (1,250 mg orally once daily on a continuous basis) in a 4-week cycle for a planned minimum of six cycles was performed. However, during the ongoing safety review of the first five patients, Grade 3 toxicities were observed in all five patients (four with neutropenia and one with neutropenic fever and diarrhea) and the decision was made to reduce the dose of both study drugs. All subsequent patients (*n* = 55) received *nab*-paclitaxel (100 mg/m^2^ IV on Day 1, 8, and 15 every 28 days) in combination with lapatinib (1,000 mg orally once daily on a continuous basis) in a 4-week cycle for a minimum of six cycles. If a complete response (CR) was obtained before six cycles, the patient had to receive two additional cycles of the combination regimen after which the CR was confirmed (a minimum of four cycles). After six cycles, patients continued to receive a daily dose of lapatinib 1,000 mg orally until disease progression or withdrawal from study due to unacceptable toxicity or consent withdrawal. Patients could also continue to receive *nab*-paclitaxel after six cycles if there was benefit without unacceptable toxicity.

Efficacy assessments were performed every 8 weeks and at the end of investigational treatment. All patients are being followed for survival. Lapatinib treatment delays of up to 2 weeks were permitted for resolution of toxicities, other than in the event of protocol defined liver abnormalities, left ventricular cardiac dysfunction, or interstitial pneumonitis. Only one dose reduction of both lapatinib (to 750 mg) and *nab*-paclitaxel (to 80 mg/m^2^) was permitted for related toxicity.

Safety assessments were performed throughout the study and included physical examinations, Eastern Cooperative Oncology Group (ECOG) performance status (PS), vital signs, clinical laboratory evaluations, cardiac monitoring (left ventricular ejection fraction function at 12-week intervals for patients while receiving lapatinib), and recording of adverse events (AEs) and serious AEs (SAEs).

Patient population {#Sec4}
------------------

Female patients ≥18 years of age with histologically confirmed HER2-positive invasive breast cancer (defined as HER2 positive score \[\>2.2\] by fluorescence in situ hybridization or 3+ amplification by immunohistochemistry) who presented with de novo stage IV disease or had stage IV disease at a relapse after curative-intent surgery were enrolled in the study.

Patients were required to have received no more than one prior chemotherapeutic regimen in the metastatic setting. Prior endocrine therapy or trastuzumab treatment in the neoadjuvant, adjuvant, or metastatic setting was permitted. If a taxane had been previously administered, progression must have occurred ≥12 months after completion of this treatment. Patients were also required to have an ECOG PS of 0 or 1, and measurable disease, according to Response Evaluation Criteria in Solid Tumors version 1.0 guidelines \[[@CR24]\]. A cardiac ejection fraction of at least 50 %, as measured by echocardiogram or multigated acquisition scan, within the institutional range of normal was also essential. Patients with stable CNS metastases (stable for at least 3 months) were eligible if they were not taking steroids or enzyme-inducing anticonvulsants. Bisphosphonate therapy for bone metastases was allowed. However, treatment must have been initiated prior to the first dose of study medication. Key exclusion criteria included active cardiac, hepatic, or biliary diseases, concurrent treatment with other anticancer or investigational agents, peripheral neuropathy of Common Terminology Criteria for Adverse Events Grade 2 or greater, and diseases or surgeries affecting gastrointestinal function including malabsorption syndrome, gastric resection, and uncontrolled inflammatory bowel disease.

Study endpoints {#Sec5}
---------------

The primary efficacy endpoint was overall response rate (ORR), based on confirmed responses from investigator assessment of best overall response. ORR was defined as the percentage of patients having either a CR or partial response (PR). Secondary efficacy endpoints included PFS (defined as time from the start of treatment until the earliest date of disease progression or death due to any cause, if sooner), OS (defined as time from the start of treatment until death due to any cause), duration of response (DoR) (defined for the subset of patients who show a CR or PR---time from first documented evidence of CR or PR until the first documented sign of disease progression or death due to any cause), and time to response (TTR) (defined for the subset of patients who show a CR or PR as time from the start of treatment until first documented evidence of PR or CR, whichever is recorded first). When tumor response was confirmed at a repeat assessment, the TTR was taken to be the first time the response was observed. Time to progression (TTP) (defined as time from the start of treatment until the earliest date of disease progression, or death due to breast cancer, if sooner) was also included as another secondary efficacy endpoint.

Statistical analyses {#Sec6}
--------------------

All efficacy analyses were conducted on the intent-to-treat population, which comprised all patients who received at least one dose of study drug. Exact binomial 95 % confidence interval (CI) for the overall response rate was used. The Kaplan--Meier estimate for the median PFS, OS, DoR, TTR, and TTP were summarized, along with approximate 95 % CI, if there were a sufficient number of events. The estimate of the standard error was computed by Greenwood's formula \[[@CR25]\]. The study was not designed for inference testing. Sample-size considerations were based entirely on feasibility. No statistical hypotheses were tested, and the focus was to estimate the ORR who received no more than 1 prior treatment for HER2-positive MBC. A sample size of 60 was targeted to insure that the lower limit of the 95 % CI exceeded 50 % for the overall response rate.

Results {#Sec7}
=======

Patient population {#Sec8}
------------------

From July 2, 2008 to January 5, 2011, 60 patients were enrolled and treated at 14 centers in the United States. Patient demographics and prior anticancer treatments are summarized in Table [1](#Tab1){ref-type="table"}. The median time from initial diagnosis (any stage) was 28.9 months; 25 % of the patients had previously received one prior regimen in the metastatic setting and 57 % of patients had previously received neo/adjuvant therapy. Disease burden at baseline is shown in Table [2](#Tab2){ref-type="table"}. The most common sites of metastatic disease were lymph nodes, followed by the lung, liver, bone, and breast.Table 1Patient demographics and prior anticancer therapiesCharacteristicLapatinib + *nab*-paclitaxel (*n* = 60)^a^Age, years Median (range)56 (28--80)HER2 status, *n* (%) FISH+ (with or without IHC+)37 (62) IHC 3+ (only)23 (38)ER/PgR status, *n* (%) ER+ and/or PgR+34 (57) ER− and PgR−26 (43)Line of metastatic treatment, *n* (%) First-line45 (75) Second-line15 (25)Median time since first diagnosis, months28.9Prior anticancer therapy, *n* (%)34 (57) Chemotherapy  Neo-/adjuvant31 (52)  Metastatic8 (13)  Neo-/adjuvant/metastatic4 (7) Taxanes  Neo-/adjuvant22 (37)  Metastatic4 (7)  Neo-/adjuvant/metastatic2 (3) Hormonal  Neo-/adjuvant17 (28)  Metastatic8 (13)  Neo-/adjuvant/metastatic5 (8) Trastuzumab  Neo-/adjuvant18 (30)  Metastatic10 (17)  Neo-adjuvant/metastatic3 (5)*ER* estrogen receptor, *FISH* fluorescence in situ hybridization, *HER2* Human epidermal growth factor receptor 2, *IHC* immunochemistry, *PgR* progesterone receptor^a^All patients were femaleTable 2Disease burden at time of study enrollmentLapatinib + *nab*-paclitaxel (*n* = 60)Number of organs involved, *n* (%) 112 (20) 225 (42) ≥323 (38)Sites of disease, *n* (%) Lymph nodes38 (63) Lung32 (53) Liver24 (40) Bone16 (27) Breast (de novo Stage IV)12 (20)

Primary efficacy results: overall tumor response rate {#Sec9}
-----------------------------------------------------

Lapatinib + *nab*-paclitaxel was efficacious with respect to investigator-assessed ORR (53 % \[*n* = 32, 95 % CI 40.7--66.0\]) with the majority of patients having a PR (28; 47 %), four patients (7 %) a CR and ten patients (17 %) showing stable disease (SD) (Table [3](#Tab3){ref-type="table"}). A total of ten patients had unknown responses. These were patients who withdrew on or before the first response assessment time point of 8 weeks with no tumor assessments available with the exception of one patient who withdrew at week 9 due to diarrhea and refused to have the bone scans.Table 3Efficacy results (ITT population)CharacteristicLapatinib + *nab*-paclitaxel (*n* = 60)Overall response rate (ORR) Response rate (CR + PR), *n* (%) (95 % CI)32 (53) (40.7--66.0) Best response, *n* (%)  CR4 (7)  PR28 (47)  SD10 (17)  PD8 (13)  Unknown10 (17)^a^PFS Patients, *n* (%)60 (100)  Progressed or died due to any cause30 (50)  Censored, follow-up ended19 (32)  Censored, follow-up ongoing11 (18)^b^ Kaplan--Meier estimate for PFS (weeks)  Median (95 % CI)39.7 (34.1--63.9)TTR Patients, *n* (%)32 (53) Kaplan--Meier estimate for TTR (weeks)  Median (95 % CI)7.8 (7.4--8.1)DoR Patients, *n* (%)32 (53)  Progressed or died due to any cause17 (53)  Censored, follow-up ended4 (13)  Censored, follow-up ongoing11 (34)^b^ Kaplan--Meier estimate for DoR (weeks)  Median (95 % CI)48.7 (31.7--57.1)TTP Patients, *n* (%)60 (100)  Progressed or died due to breast cancer28 (47)  Censored, died due to other cause2 (3)  Censored, follow-up ended19 (32)  Censored, follow-up ongoing11 (18)^b^ Kaplan--Meier estimate for TTP (weeks)  Median (95 % CI)41.0 (39.1--64.6)*CI* confidence interval, *CR* complete response, *DoR* duration of response, *ITT* intent-to-treat, *PD* progressive disease, *PFS* progression-free survival, *PR* partial response, *SD* stable disease, *TTR* time to response, *TTP* time to progression^a^Patients who withdrew before the first response assessment. Patients with unknown responses were treated as non-responders^b^At the time of this reporting, there were 11 patients still ongoing on lapatinib monotherapy treatment

Secondary efficacy results {#Sec10}
--------------------------

The median Kaplan--Meier estimate of investigator-assessed PFS was 39.7 weeks (95 % CI 34.1--63.9) (Table [3](#Tab3){ref-type="table"}). As of the data cut-off, 13 patients (22 %) had died. Therefore, the median OS was not reached as the data were not mature (i.e., \>75 % of the patients were censored for the endpoint). The median Kaplan--Meier estimate of investigator-assessed TTR and DoR was 7.8 weeks (95 % CI 7.4--8.1) and 48.7 weeks (95 % CI 31.7--57.1) for patients who responded (CR or PR). The Kaplan--Meier estimate for median TTP was 41 weeks (95 % CI 39.1--64.6). TTP was similar to PFS in this study as the majority of PFS events (either progression or death due to any cause) were disease progressions (28 out of 30). Two PFS events were deaths due to causes other than breast cancer and were considered a competing risk for the TTP analysis.

Lapatinib and *nab*-paclitaxel exposure {#Sec11}
---------------------------------------

The median duration of exposure to lapatinib was 5.6 months (range, 0--19 months). The mean daily lapatinib dose was 893.1 mg. Approximately half of the study population (31 patients; 52 %) completed six cycles of treatment with *nab*-paclitaxel, which was the duration of treatment specified in the protocol. A total of 13 patients (22 %) continued to participate in the study for further cycles of treatment. In total, 73 lapatinib dose interruptions occurred in 34 patients (57 %) were of short duration (51/73 interruptions were ≤7 days in duration), and were mainly due to non-hematologic toxicities (52 %). Twenty-six reductions in the dose of lapatinib were made in 24 patients (40 %) and were also mainly due to non-hematologic toxicities (85 %). Twenty-four doses of *nab*-paclitaxel were delayed in 15 patients (25 %), and were most commonly due to non-hematologic toxicity (42 %). Sixteen dose reductions of *nab*-paclitaxel occurred in 13 patients (22 %) mainly due to hematologic toxicities (56 %). Doses of *nab*-paclitaxel were missed by 33 patients (55 %) and the majority of these patients missed one or two doses (53 missed doses in total). The most common reason for missing a dose was non-hematologic toxicity (47 %).

Safety {#Sec12}
------

The most commonly reported AEs were diarrhea, fatigue, nausea, and rash (Table [4](#Tab4){ref-type="table"}). The maximum toxicity grade of the majority of frequently reported AEs was Grade 1 or 2. Grade 3 diarrhea was reported at a frequency of 20 %, contributing to a high overall frequency (62 %) of AEs with a maximum toxicity Grade of 3. AEs of neutropenia also reached a maximum toxicity Grade of 3 for 22 % of patients. A total of five patients (8 %) experienced Grade 4 events (diarrhea, nausea, fatigue, febrile neutropenia, and hypokalemia) and all these AEs were considered treatment-related.Table 4AEs with \>15 % incidence by maximum toxicity grade (ITT population)Adverse eventsNumber of subjects (%)Lapatinib + *nab*-paclitaxel (*n* = 60)Grade 1Grade 2Grade 3Grade 4Diarrhea (*n* = 54)3830202Fatigue (*n* = 41)401882Nausea (*n* = 39)382322Rash (*n* = 29)251850Alopecia (*n* = 24)152500Vomiting (*n* = 23)25850Anemia (*n* = 22)171820Neutropenia (*n* = 22)510220Neuropathy peripheral (*n* = 21)201230Edema peripheral (*n* = 16)151200Cough (*n* = 15)20500Dyspnea (*n* = 15)15550Decreased appetite (*n* = 15)101320Constipation (*n* = 13)20200Epistaxis (*n* = 13)22000Nail disorder (*n* = 13)13800Dehydration (*n* = 12)01370Weight decreased (*n* = 11)10720Pyrexia (*n* = 11)15300Insomnia (*n* = 11)15300Dyspepsia (*n* = 10)15200Pain in extremity (*n* = 10)12500Dysgeusia (*n* = 10)13300*AE* adverse event, *ITT* intent-to-treat

Eighteen patients (30 %) reported SAEs (Table [5](#Tab5){ref-type="table"}). The most frequently reported SAEs were dehydration (*n* = 3; 5 %) and diarrhea (*n* = 3; 5 %).Table 5Serious adverse events (SAEs)Lapatinib + *nab*-paclitaxel (*n* = 60)Any SAE, *n* (%)18 (30)With ≥2 (3 %) patients, *n* (%) Dehydration3 (5) Diarrhea3 (5) Anemia2 (3) Cellulitis2 (3) Febrile neutropenia2 (3) Hypokalemia2 (3) Renal failure acute2 (3)Drug-related fatal SAEs, *n* (%)2 (3)^a^Irrespective of relationship to study treatment^a^One patient (lapatinib 750 mg/day, *nab*-paclitaxel 100 mg/m^2^ weekly) with a history of arrhythmia experienced a sudden death of presumed cardiac origin. One patient (lapatinib 1,000 mg/day, *nab*-paclitaxel 100 mg/m^2^ weekly) with uncontrolled diabetes developed acute renal failure and dehydration

Forty-nine patients (82 %) discontinued study treatment, predominantly due to disease progression (28 patients), and 10/49 patients (17 %) experienced an AE that led to the permanent discontinuation of study treatment (Table [6](#Tab6){ref-type="table"}). Overall, 13 deaths were reported in this study with the primary cause of death due to breast cancer (*n* = 10/13; 17 %). Two patients (3 %) died due to SAEs (sudden death, acute renal failure) which were considered to be related to treatment. There were no clinically significant changes in vital signs, body weight, and ECOG PS during the study.Table 6Study treatment overviewLapatinib + *nab*-paclitaxel (*n* = 60)Discontinued study treatment, *n* (%)49 (82)Ongoing, *n* (%)11 (18)^a^Reason for discontinuation, *n* (%) Disease progression28 (47) Adverse events10 (17) Decision by patient6 (10) Protocol deviation^b^3 (5) Investigator decision2 (3)^a^At the time of this reporting, there were 11 patients continuing on the lapatinib monotherapy^b^Two patients off study treatment for longer than the protocol defined 2 weeks; one patient received radiation to the right breast while on study

Discussion {#Sec13}
==========

The primary objective of this study was to determine the ORR in patients with HER2-positive MBC who received first-line or second-line treatment with lapatinib in combination with weekly *nab*-paclitaxel. This study was not designed for inference testing thus definitive conclusions cannot be derived from the results. A clinical benefit was observed for treatment with lapatinib plus *nab*-paclitaxel with respect to investigator-assessed ORR in 32 patients (53 %). The highest number of responses was PR (28 patients; 47 %). Four patients (7 %) had a CR and ten patients (17 %) showed SD.

ORR in this study was lower compared with other studies conducted to investigate paclitaxel and lapatinib combination therapy. In a Phase III, multicenter, double-blind, placebo-controlled study in which patients with HER2-positive MBC (Stage IV) received treatment with paclitaxel and either lapatinib or placebo (NCT00281658), ORR was 69 % \[[@CR26]\].

In a Phase II study in which 57 female patients with HER2-positive MBC (Stage IV) were randomized to receive paclitaxel and lapatinib (NCT00356811) ORR was 77 % \[[@CR27]\]. These differences could be due in part to the small sample size, confounded by the inclusion of both first-line and second-line patients and the fact that ten patients in this study had an unknown response (no tumor assessments available).

The clinically meaningful activity observed in the primary endpoint was supported by investigator-assessed PFS, where the median Kaplan--Meier estimate of PFS was 39.7 weeks. These results are consistent with those of other trials evaluating paclitaxel and lapatinib combination therapy. In two similar studies, the median PFS were 9.7 months (41.7 weeks) (NCT00281658) \[[@CR26]\] and 47.9 weeks (NCT00356811) \[[@CR27]\].

The median duration of lapatinib and *nab*-paclitaxel treatment was 24.3 and 24 weeks, respectively. These data are comparable to results from a randomized, multicenter, double-blind, placebo-controlled, 2-Arm, Phase III Study of lapatinib in combination with paclitaxel in subjects previously untreated for advanced or MBC (NCT00075270) \[[@CR28]\]. In this study, the median duration of lapatinib treatment was 19.9 weeks, and the median duration of paclitaxel treatment was 15.1 and 16.1 weeks in the paclitaxel-lapatinib and paclitaxel-placebo arms, respectively.

The maximum toxicity grade of the majority of AEs was Grade 3 or less, and most resolved without sequelae. For hematologic toxicities, Grade 3 neutropenia and anemia was observed in 22 and 2 % of patients, respectively, which was lower compared with 35 and 4 % observed in the lapatinib plus paclitaxel study (NCT00281658) \[[@CR26]\]. However, the non-hematologic toxicities observed in this study were consistent with the NCT00281658 study \[[@CR26]\]. Grade 3 diarrhea, rash, and fatigue were reported by 20, 5, and 8 % of the patients, respectively, in this study compared with 20, 4, and 2 % in the NCT00281658 study. Although Grade 3 AEs of diarrhea and neutropenia were reported by 20 and 22 % of patients, respectively, low numbers of patients withdrew due to these AEs (7 % due to diarrhea, none due to neutropenia). SAEs were reported by 30 % of patients. The most frequently reported SAEs were dehydration (5 %) and diarrhea (5 %). Two patients died during the study due to SAEs (sudden death in a patient with a medical history of cardiac arrhythmias, and acute renal failure in a patient with a medical history of uncontrolled diabetes).

This study established a dose regimen of *nab*-paclitaxel (100 mg/m^2^ IV on Day 1, 8, and 15 every 28 days) in combination with lapatinib (1,000 mg orally once daily on a continuous basis) in a 4-week cycle as a feasible treatment for HER2-positive MBC with manageable and predictable toxicity. The incidence and severity of AEs for the combination treatment was considered to be consistent with the known safety profiles of lapatinib and *nab*-paclitaxel. Overall, the data in this study are consistent with those reported for other studies of lapatinib in combination with paclitaxel. Although this study was not designed for inference testing, the results suggest a promising signal of efficacy and no new safety signals.
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